Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

After-hours movers: ZoomInfo sinks on weak guidance, Arista Networks gains on results

AuthorInvesting.com
Published 31/07/2023, 22:32
© Reuters

After-Hours Stock Movers:

ZoomInfo Technologies Inc (NASDAQ:ZI) 17% LOWER; reported Q2 EPS of $0.26, $0.03 better than the analyst estimate of $0.23. Revenue for the quarter came in at $308.6 million versus the consensus estimate of $310.94M. Announces $500M Share Repurchase Program ZoomInfo Technologies Inc. sees Q3 2023 EPS of $0.24-$0.25, versus the consensus of $0.25. ZoomInfo Technologies Inc. sees Q3 2023 revenue of $309-312M, versus the consensus of $325.8M. ZoomInfo Technologies Inc. sees FY2023 EPS of $0.99-$1.00, versus the consensus of $1.00. ZoomInfo Technologies Inc. sees FY2023 revenue of $1.225-1.235 billion, versus the consensus of $1.28B.

Harmonic (NASDAQ:HLIT) 15% LOWER; reported Q2 EPS of $0.12, $0.01 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $156M versus the consensus estimate of $167.52M. Harmonic sees Q3 2023 EPS of ($0.02)-$0.02, versus the consensus of $0.19. Harmonic sees Q3 2023 revenue of $125-140M, versus the consensus of $188.6M. Harmonic sees FY2023 EPS of $0.38-$0.52, versus the consensus of $0.69. Harmonic sees FY2023 revenue of $620-660M, versus the consensus of $723.2M.

Arista Networks (NYSE:ANET) 10% HIGHER; reported Q2 EPS of $1.58, $0.14 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.46B versus the consensus estimate of $1.38B. Arista Networks sees Q3 2023 revenue of $1.45-1.5B, versus the consensus of $1.391B.

Emergent Biosolutions Inc (NYSE:EBS) 8% HIGHER; announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at up to a maximum of $704M, for advanced development, manufacturing scale-up, and procurement of Ebanga (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Trex Company Inc (NYSE:TREX) 5% HIGHER; reported Q2 EPS of $0.71, $0.17 better than the analyst estimate of $0.54. Revenue for the quarter came in at $357M versus the consensus estimate of $318.89M. Trex sees Q3 2023 revenue of $280-290M, versus the consensus of $264.22M. Trex sees FY2023 revenue of $1.04-1.06B, versus the consensus of $1.05B.

Yum China Holdings Inc (NYSE:YUMC) 4% LOWER; reported Q2 EPS of $0.47, $0.01 better than the analyst estimate of $0.46. Revenue for the quarter came in at $2.65B versus the consensus estimate of $2.72B.

Avis Budget Group (NASDAQ:CAR) 2% HIGHER; reported Q2 EPS of $11.01, $1.57 better than the analyst estimate of $9.44. Revenue for the quarter came in at $3.12B versus the consensus estimate of $3.21B.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.